These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 1557932)

  • 21. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategy for cross-protection among Shigella flexneri serotypes.
    Noriega FR; Liao FM; Maneval DR; Ren S; Formal SB; Levine MM
    Infect Immun; 1999 Feb; 67(2):782-8. PubMed ID: 9916090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
    DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
    Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentials of Shigella flexneri Y strain TSF21 as a candidate vaccine against shigellosis: safety, immunogenicity and protective efficacy in Bonnet monkeys.
    Ashraf MM; Giri DK; Batra HV; Khandekar P; Ahmed ZU; Talwar GP
    FEMS Microbiol Immunol; 1991 Jun; 3(3):165-70. PubMed ID: 1878259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
    Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005728. PubMed ID: 28727722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
    Coster TS; Hoge CW; VanDeVerg LL; Hartman AB; Oaks EV; Venkatesan MM; Cohen D; Robin G; Fontaine-Thompson A; Sansonetti PJ; Hale TL
    Infect Immun; 1999 Jul; 67(7):3437-43. PubMed ID: 10377124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
    Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
    Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis.
    Sansonetti PJ; Arondel J
    Vaccine; 1989 Oct; 7(5):443-50. PubMed ID: 2683460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as a candidate live-attenuated oral vaccine.
    Yoshikawa M; Sasakawa C; Okada N; Takasaka M; Nakayama M; Yoshikawa Y; Kohno A; Danbara H; Nariuchi H; Shimada H
    Vaccine; 1995; 13(15):1436-40. PubMed ID: 8578822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes.
    Verma NK; Lindberg AA
    Vaccine; 1991 Jan; 9(1):6-9. PubMed ID: 2008803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An outbreak of Sonne shigellosis in a population receiving oral attenuated shigella vaccines.
    Levine MM; Rice PA; Gangarosa EJ; Morris GK; Snyder MJ; Formal SB; Wells JG; Gemski P; Hammond J
    Am J Epidemiol; 1974 Jan; 99(1):30-6. PubMed ID: 4590191
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
    Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
    Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulated Delayed
    Su H; Liu Q; Wang S; Curtiss R; Kong Q
    Theranostics; 2019; 9(12):3565-3579. PubMed ID: 31281498
    [No Abstract]   [Full Text] [Related]  

  • 35. Expression of Shigella dysenteriae serotype 1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes.
    Fält IC; Schweda EK; Klee S; Singh M; Floderus E; Timmis KN; Lindberg AA
    J Bacteriol; 1995 Sep; 177(18):5310-5. PubMed ID: 7545156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M; Janardhanan J; Wagh C; Verma S; Charles RC; Leung DT; Kamruzzaman M; Pansuriya RK; Chowdhury F; Vann WF; Kaminski RW; Khan AI; Bhuiyan TR; Qadri F; Kováč P; Xu P; Ryan ET
    Vaccine; 2024 Oct; 42(24):126263. PubMed ID: 39217775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV; Roberts F; Verma NK
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei.
    Formal SB; Oaks EV; Olsen RE; Wingfield-Eggleston M; Snoy PJ; Cogan JP
    J Infect Dis; 1991 Sep; 164(3):533-7. PubMed ID: 1869840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
    Noriega FR; Losonsky G; Wang JY; Formal SB; Levine MM
    Infect Immun; 1996 Jan; 64(1):23-7. PubMed ID: 8557344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.
    Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB
    Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.